First-in-Human Study of <sup>18</sup>F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding.
Where this comes from
- Record sourced from PubMed, PMID 38360052.
- Also identified by DOI 10.2967/jnumed.123.266470 and PMC identifier 10924160.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PET imaging of synaptic vesicle glycoprotein 2A allows for noninvasive quantification of synapses. This first-in-human study aimed to evaluate the kinetics, test-retest reproducibility, and extent of specific binding of a recently developed synaptic vesicle glycoprotein 2A PET ligand, (<i>R</i>)-4-(3-(<sup>18</sup>F-fluoro)phenyl)-1-((3-methylpyridin-4-yl)methyl)pyrrolidine-2-one (<sup>18</sup>F-SynVesT-2), with fast brain kinetics. <b>Methods:</b> Nine healthy volunteers participated in this study and were scanned on a High Resolution Research Tomograph scanner with <sup>18</sup>F-SynVesT-2. Five volunteers were scanned twice on 2 different days. Five volunteers were rescanned with preinjected levetiracetam (20 mg/kg, intravenously). Arterial blood was collected to calculate the plasma free fraction and generate the arterial input function. Individual MR images were coregistered to a brain atlas to define regions of interest for generating time-activity curves, which were fitted with 1- and 2-tissue-compartment (1TC and 2TC) models to derive the regional distribution volume (<i>V</i> <sub>T</sub>). The regional nondisplaceable binding potential (<i>BP</i> <sub>ND</sub>) was calculated from 1TC <i>V</i> <sub>T</sub>, using the centrum semiovale (CS) as the reference region. <b>Results:</b> <sup>18</sup>F-SynVesT-2 was synthesized with high molar activity (187 ± 69 MBq/nmol, <i>n</i> = 19). The parent fraction of <sup>18</sup>F-SynVesT-2 in plasma was 28% ± 8% at 30 min after injection, and the plasma free fraction was high (0.29 ± 0.04). <sup>18</sup>F-SynVesT-2 entered the brain quickly, with an SUV<sub>peak</sub> of 8 within 10 min after injection. Regional time-activity curves fitted well with both the 1TC and the 2TC models; however, <i>V</i> <sub>T</sub> was estimated more reliably using the 1TC model. The 1TC <i>V</i> <sub>T</sub> ranged from 1.9 ± 0.2 mL/cm<sup>3</sup> in CS to 7.6 ± 0.8 mL/cm<sup>3</sup> in the putamen, with low absolute test-retest variability (6.0% ± 3.6%). Regional <i>BP</i> <sub>ND</sub> ranged from 1.76 ± 0.21 in the hippocampus to 3.06 ± 0.29 in the putamen. A 20-min scan was sufficient to provide reliable <i>V</i> <sub>T</sub> and <i>BP</i> <sub>ND</sub> <b>Conclusion:</b> <sup>18</sup>F-SynVesT-2 has fast kinetics, high specific uptake, and low nonspecific uptake in the brain. Consistent with the nonhuman primate results, the kinetics of <sup>18</sup>F-SynVesT-2 is faster than the kinetics of <sup>11</sup>C-UCB-J and <sup>18</sup>F-SynVesT-1 in the human brain and enables a shorter dynamic scan to derive physiologic information on cerebral blood flow and synapse density.